In this video interview, Eva Ciruelos, MD, PhD, Hospital 12 de Octubre in Madrid, Spain, discusses unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer. She provides an overview of her talk, which covers the current standard of care for HR+/HER2- breast cancer, the unmet clinical needs in this patient population, and the potential of CDK4/6 inhibitors to address these unmet needs. Dr. Ciruelos also touches on the latest clinical trial data, the safety and efficacy of CDK4/6 inhibitors, and the ongoing efforts to optimize their use in clinical practice. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.